explore
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.
The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.
advertisement
But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Researchers test human milk's ability to repair gut microbiome
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
